# A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00585533** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 40 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Erlotinib (Tarceva)

## Key facts

- **NCT ID:** NCT00585533
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585533, "A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00585533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*